Oncol-话题@MedSci

#Oncol#

2384篇内容 | 2454人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1866474, encodeId=225c18664e43a, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncol：吡咯替尼治疗乳腺癌脑转移，患者获益明显, objectType=article, longId=294866, objectId=f9572948661c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f9572948661c, replyNumber=0, likeNumber=87, createdTime=2022-02-15, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f9572948661c, moduleTitle=Lancet Oncol：吡咯替尼治疗乳腺癌脑转移，患者获益明显, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f9572948661c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866375, encodeId=359018663e589, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：纳武单抗联合伊匹单抗治疗晚期黑色素瘤, objectType=article, longId=221149, objectId=c9542211494e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c9542211494e, replyNumber=0, likeNumber=94, createdTime=2022-01-31, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c9542211494e, moduleTitle=J Clin Oncol：纳武单抗联合伊匹单抗治疗晚期黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c9542211494e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866536, encodeId=062d1866536de, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：ICI联合VEGFR抑制剂治疗晚期肾细胞癌时的主要不良心血管事件风险, objectType=article, longId=300189, objectId=ad87300189e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad87300189e8, replyNumber=0, likeNumber=105, createdTime=2023-02-19, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad87300189e8, moduleTitle=J Clin Oncol：ICI联合VEGFR抑制剂治疗晚期肾细胞癌时的主要不良心血管事件风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad87300189e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866077, encodeId=c9be18660e7d9, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncol：伊匹单抗联合抗PD-1疗法显著改善了对抗PD-1耐药的晚期黑色素瘤患者的临床预后, objectType=article, longId=211183, objectId=ec8c211183ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec8c211183ba, replyNumber=0, likeNumber=68, createdTime=2022-04-22, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec8c211183ba, moduleTitle=Lancet Oncol：伊匹单抗联合抗PD-1疗法显著改善了对抗PD-1耐药的晚期黑色素瘤患者的临床预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec8c211183ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866322, encodeId=97c31866322c0, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：肝切除术(HR)对比TACE治疗中期肝细胞癌(IM-HCC)的疗效, objectType=article, longId=219491, objectId=16ac219491e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16ac219491e4, replyNumber=0, likeNumber=60, createdTime=2022-06-10, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16ac219491e4, moduleTitle=Front Oncol：肝切除术(HR)对比TACE治疗中期肝细胞癌(IM-HCC)的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=16ac219491e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866392, encodeId=bccc1866392ad, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=JAMA Oncol：局部晚期结直肠癌的全新辅助疗法——放化疗+诱导/巩固化疗！, objectType=article, longId=221421, objectId=c3fc22142171, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c3fc22142171, replyNumber=0, likeNumber=85, createdTime=2022-04-17, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c3fc22142171, moduleTitle=JAMA Oncol：局部晚期结直肠癌的全新辅助疗法——放化疗+诱导/巩固化疗！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c3fc22142171)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866108, encodeId=525b18661084f, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=JAMA Oncol：帕博利珠单抗（Pembrolizumab）联合同步放化疗(cCRT)治疗不可切除的III期NSCLC的疗效和安全性: KEYNOTE-799。, objectType=article, longId=212429, objectId=7a5c212429e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a5c212429e5, replyNumber=0, likeNumber=67, createdTime=2021-06-16, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a5c212429e5, moduleTitle=JAMA Oncol：帕博利珠单抗（Pembrolizumab）联合同步放化疗(cCRT)治疗不可切除的III期NSCLC的疗效和安全性: KEYNOTE-799。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a5c212429e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866452, encodeId=5515186645203, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：回顾性研究比较白蛋白结合紫杉醇和多西他赛作为新辅助治疗治疗HER2-乳腺癌患者的疗效, objectType=article, longId=293860, objectId=16d129386032, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16d129386032, replyNumber=0, likeNumber=0, createdTime=2022-01-16, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16d129386032, moduleTitle=Front Oncol：回顾性研究比较白蛋白结合紫杉醇和多西他赛作为新辅助治疗治疗HER2-乳腺癌患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=16d129386032)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866445, encodeId=6a54186644538, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Ther Adv Med Oncol：揭示HER2+晚期乳腺癌患者20年治疗方式和临床预后（PANHER研究）, objectType=article, longId=293422, objectId=a555293422c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a555293422c3, replyNumber=0, likeNumber=66, createdTime=2022-06-06, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a555293422c3, moduleTitle=Ther Adv Med Oncol：揭示HER2+晚期乳腺癌患者20年治疗方式和临床预后（PANHER研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a555293422c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866407, encodeId=3244186640e07, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：T-DM1+帕妥珠单抗 vs 紫杉类+曲妥珠单抗+帕妥珠单抗治疗高危HER2+早期乳腺癌患者的疗效和安全性：III期临床研究KAITLIN, objectType=article, longId=265037, objectId=970226503ec6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=970226503ec6, replyNumber=0, likeNumber=78, createdTime=2022-10-01, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=970226503ec6, moduleTitle=J Clin Oncol：T-DM1+帕妥珠单抗 vs 紫杉类+曲妥珠单抗+帕妥珠单抗治疗高危HER2+早期乳腺癌患者的疗效和安全性：III期临床研究KAITLIN, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=970226503ec6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866406, encodeId=6d4b1866406a4, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncol：全球年轻人癌症负担发布，每年致死40万人, objectType=article, longId=265022, objectId=06e526502212, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=06e526502212, replyNumber=0, likeNumber=110, createdTime=2022-02-24, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=06e526502212, moduleTitle=Lancet Oncol：全球年轻人癌症负担发布，每年致死40万人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=06e526502212)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866053, encodeId=b50a186605387, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet oncol：多种放化疗联合方案治疗局部晚期头颈癌的疗效对比, objectType=article, longId=210448, objectId=c74521044816, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c74521044816, replyNumber=0, likeNumber=75, createdTime=2021-12-23, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c74521044816, moduleTitle=Lancet oncol：多种放化疗联合方案治疗局部晚期头颈癌的疗效对比, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c74521044816)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866101, encodeId=903b186610147, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncology：Avelumab联合同步放化疗与单纯同步放化疗治疗局部晚期头颈部鳞状细胞癌：一项随机、双盲、安慰剂对照、多中心、3期试验 , objectType=article, longId=212089, objectId=fc5c2120893c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc5c2120893c, replyNumber=0, likeNumber=49, createdTime=2021-11-01, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc5c2120893c, moduleTitle=Lancet Oncology：Avelumab联合同步放化疗与单纯同步放化疗治疗局部晚期头颈部鳞状细胞癌：一项随机、双盲、安慰剂对照、多中心、3期试验 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc5c2120893c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866435, encodeId=7b0b18664356f, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：安罗替尼（Anlotinib）治疗中国复发或转移性宫颈癌患者中的有效性和安全性, objectType=article, longId=293022, objectId=95b02930227c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=95b02930227c, replyNumber=0, likeNumber=56, createdTime=2022-03-17, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=95b02930227c, moduleTitle=Front Oncol：安罗替尼（Anlotinib）治疗中国复发或转移性宫颈癌患者中的有效性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=95b02930227c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866074, encodeId=532f18660e4bc, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Ther Adv Med Oncol：激素受体状态会影响高BMI和高血糖对早期HER2+乳腺癌患者肿瘤复发风险的影响, objectType=article, longId=210916, objectId=b038210916f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b038210916f9, replyNumber=0, likeNumber=62, createdTime=2021-09-17, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b038210916f9, moduleTitle=Ther Adv Med Oncol：激素受体状态会影响高BMI和高血糖对早期HER2+乳腺癌患者肿瘤复发风险的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b038210916f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866063, encodeId=0f6b1866063c9, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Thorac Oncol：布里加替尼治疗晚期ALK+NSCLC患者的初步结果, objectType=article, longId=210605, objectId=efad2106052b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=efad2106052b, replyNumber=0, likeNumber=78, createdTime=2022-01-22, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=efad2106052b, moduleTitle=J Thorac Oncol：布里加替尼治疗晚期ALK+NSCLC患者的初步结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=efad2106052b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866142, encodeId=77f61866142c5, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Ann Oncol:紫杉醇联合或不联合atezolizumab一线治疗不可切除、局部晚期或转移性三阴性乳腺癌的疗效: IMpassion131初次分析, objectType=article, longId=213741, objectId=328f213e41bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=328f213e41bd, replyNumber=0, likeNumber=75, createdTime=2022-05-29, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=328f213e41bd, moduleTitle=Ann Oncol:紫杉醇联合或不联合atezolizumab一线治疗不可切除、局部晚期或转移性三阴性乳腺癌的疗效: IMpassion131初次分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=328f213e41bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866119, encodeId=91ab18661199c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Radiotherapy and Oncology:儿童幕下肿瘤幸存者的与神经认知受损相关的脑网络中枢可能是治疗靶点, objectType=article, longId=212950, objectId=e80f21295036, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e80f21295036, replyNumber=0, likeNumber=59, createdTime=2021-08-17, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e80f21295036, moduleTitle=Radiotherapy and Oncology:儿童幕下肿瘤幸存者的与神经认知受损相关的脑网络中枢可能是治疗靶点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e80f21295036)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866308, encodeId=7ff818663088f, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：阿帕替尼（Apatinib）治疗既往治疗过的晚期乳腺癌患者的疗效和安全性, objectType=article, longId=219105, objectId=f9f621910501, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f9f621910501, replyNumber=0, likeNumber=55, createdTime=2022-01-10, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f9f621910501, moduleTitle=Front Oncol：阿帕替尼（Apatinib）治疗既往治疗过的晚期乳腺癌患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f9f621910501)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866161, encodeId=be011866161ac, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：CMB305联合阿特珠单抗治疗局部晚期滑膜肉瘤或粘液样脂肪肉瘤患者的疗效和安全性, objectType=article, longId=214523, objectId=8b672145231c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b672145231c, replyNumber=0, likeNumber=71, createdTime=2022-04-03, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b672145231c, moduleTitle=J Clin Oncol：CMB305联合阿特珠单抗治疗局部晚期滑膜肉瘤或粘液样脂肪肉瘤患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b672145231c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Oncol

2020-05-29

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncol：吡咯替尼治疗乳腺癌脑转移，患者获益明显

2022-02-15

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：纳武单抗联合伊匹单抗治疗晚期黑色素瘤

2022-01-31

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：ICI联合VEGFR抑制剂治疗晚期肾细胞癌时的主要不良心血管事件风险

2023-02-19

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncol：伊匹单抗联合抗PD-1疗法显著改善了对抗PD-1耐药的晚期黑色素瘤患者的临床预后

2022-04-22

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：肝切除术(HR)对比TACE治疗中期肝细胞癌(IM-HCC)的疗效

2022-06-10

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

JAMA Oncol：局部晚期结直肠癌的全新辅助疗法——放化疗+诱导/巩固化疗！

2022-04-17

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

JAMA Oncol：帕博利珠单抗（Pembrolizumab）联合同步放化疗(cCRT)治疗不可切除的III期NSCLC的疗效和安全性: KEYNOTE-799。

2021-06-16

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：回顾性研究比较白蛋白结合紫杉醇和多西他赛作为新辅助治疗治疗HER2-乳腺癌患者的疗效

2022-01-16

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Ther Adv Med Oncol：揭示HER2+晚期乳腺癌患者20年治疗方式和临床预后（PANHER研究）

2022-06-06

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：T-DM1+帕妥珠单抗 vs 紫杉类+曲妥珠单抗+帕妥珠单抗治疗高危HER2+早期乳腺癌患者的疗效和安全性：III期临床研究KAITLIN

2022-10-01

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncol：全球年轻人癌症负担发布，每年致死40万人

2022-02-24

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet oncol：多种放化疗联合方案治疗局部晚期头颈癌的疗效对比

2021-12-23

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncology：Avelumab联合同步放化疗与单纯同步放化疗治疗局部晚期头颈部鳞状细胞癌：一项随机、双盲、安慰剂对照、多中心、3期试验

2021-11-01

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：安罗替尼（Anlotinib）治疗中国复发或转移性宫颈癌患者中的有效性和安全性

2022-03-17

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Ther Adv Med Oncol：激素受体状态会影响高BMI和高血糖对早期HER2+乳腺癌患者肿瘤复发风险的影响

2021-09-17

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Thorac Oncol：布里加替尼治疗晚期ALK+NSCLC患者的初步结果

2022-01-22

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Ann Oncol:紫杉醇联合或不联合atezolizumab一线治疗不可切除、局部晚期或转移性三阴性乳腺癌的疗效: IMpassion131初次分析

2022-05-29

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Radiotherapy and Oncology:儿童幕下肿瘤幸存者的与神经认知受损相关的脑网络中枢可能是治疗靶点

2021-08-17

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：阿帕替尼（Apatinib）治疗既往治疗过的晚期乳腺癌患者的疗效和安全性

2022-01-10

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：CMB305联合阿特珠单抗治疗局部晚期滑膜肉瘤或粘液样脂肪肉瘤患者的疗效和安全性

2022-04-03

科室
- - 订阅+
  - 更多科室
工具
服务